1-2 of 2
Karl Kreuzer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Free
Othman Al-Sawaf, Sandra Robrecht, Matthew S Davids, Mary Ann Anderson, Romain Guieze, Valeria Buccheri, Celso Arrais-Rodrigues, Francesc Bosch Albareda, Ruth Clifford, Michael Doubek, Krzysztof Jamroziak, Arnon Kater, Mattias Mattsson, Carsten Niemann, Miguel Pavlovsky, Lydia Scarfo, Renata Walewska, Peng Liu, Ki-Seong Eom, Karl Kreuzer, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Kirsten Fischer, Michael Hallek, Kenneth Wu, Marcus Lefebure, Wei Ding, Remus Vezan, Barbara Eichhorst
Journal: Blood
Blood (2025) 146 (Supplement 1): 2137.
https://doi.org/10.1182/blood-2025-2137
Published: 2025
Journal Articles

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

Free
Othman Al-Sawaf, Sandra Robrecht, Adam Giza, Anantharamanan Rajamani, Rebecca Wurm-Kuczera, Chidimma Akpa, Shashwat Sahay, Eugen Tausch, Janina Stumpf, Anna Maria Fink, Christof Schneider, Sebastian Böttcher, Martin Mikusko, Matthias Ritgen, Johannes Schetelig, Julia Von Tresckow, Ursula Vehling-Kaiser, Clemens-Martin Wendtner, Kirsten Fischer, Karl Kreuzer, Philipp Staber, Stephan Stilgenbauer, Carsten Niemann, Björn Chapuy, Michael Hallek, Barbara Eichhorst
Journal: Blood
Blood (2025) 146 (Supplement 1): 90.
https://doi.org/10.1182/blood-2025-90
Published: 2025